UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Positron Emission Tomography in Non–Small-Cell Lung Cancer: Prediction of Response to Chemotherapy by Quantitative Assessment of Glucose Use

Journal of clinical oncology, 2003-07, Vol.21 (14), p.2651-2657

2003

Volltextzugriff (PDF)

Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

Journal of clinical oncology, 2009-06, Vol.27 (17), p.2823-2830

2009

Volltextzugriff (PDF)

Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2009-09, Vol.27 (25), p.4068-4075

2009

Volltextzugriff (PDF)

Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18

Journal of clinical oncology, 2005-04, Vol.23 (12), p.2831-2839

2005

Volltextzugriff (PDF)

Onco-PDO test utilizing patient-derived organoids (PDOs) and next-generation precision oncology in breast cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e13594-e13594

2023

Volltextzugriff (PDF)

MOR202 with low-dose dexamethasone (Dex) and in combination with pomalidomide/dex and lenalidomide/dex in relapsed or refractory multiple myeloma (RRMM): Interim analysis of a phase I/IIa dose-escalation study

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.8024-8024

2017

Volltextzugriff (PDF)

Changes in the tumor glucose-uptake measured by 18F-FDG PET with two weeks of single-agent cetuximab in localized squamous cell carcinoma of the esophagus

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e15042-e15042

2013

Volltextzugriff (PDF)

MOR202 alone and in combination with pomalidomide or lenalidomide in relapsed or refractory multiple myeloma: Data from clinically relevant cohorts from a phase I/IIa study

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.8012-8012

2016

Volltextzugriff (PDF)

Is lanreotide and/or interferon alfa an adequate therapy for neuroendocrine tumors?

Journal of clinical oncology, 2004-02, Vol.22 (3), p.573; author reply 574-573

2004

Volltextzugriff (PDF)

A phase I/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.8574-8574

2015

Volltextzugriff (PDF)

Impact of pathologic complete response to preoperative docetaxel-based chemotherapy on disease-free survival in esophagogastric adenocarcinoma

Journal of clinical oncology, 2013-02, Vol.31 (4_suppl), p.123-123

2013

Volltextzugriff (PDF)

Detection of mutant-free circulating tumor DNA in the plasma of patients with gastrointestinal stromal tumor (GIST) harboring activating mutations of C-Kit or PDGFRA

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.10508-10508

2013

Volltextzugriff (PDF)

A prospective, multicenter trial of complementary and alternative medicine (CAM) utilization by patients undergoing definitive breast radiotherapy

Journal of clinical oncology, 2011-09, Vol.29 (27_suppl), p.241-241

2011

Volltextzugriff (PDF)

PET-guided treatment in locally advanced adenocarcinoma of the esophagogastric junction (AEG): The MUNICON-II study

Journal of clinical oncology, 2011-02, Vol.29 (4_suppl), p.3-3

2011

Volltextzugriff (PDF)

Weekly cetuximab (CET) plus oxaliplatin (OX), infusional 5-fluorouracil (5-FU) and radiation therapy (RT) as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A phase I study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e15507-e15507

2009

Volltextzugriff (PDF)

Impact of chemotherapy induced haematotoxicity on blood component use and associated costs in NSCLC and lymphoma patients in Germany

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.20715-20715

2008

Volltextzugriff (PDF)

Docetaxel, cisplatin and leucovorin/fluorouracil in first-line advanced gastric cancer and adenocarcinoma of the esophagogastric junction: Results of the phase II GASTRO-TAX-1 trial

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.4561-4561

2007

Volltextzugriff (PDF)

Cost analysis of febrile neutropenia (FN) management in three tumour types in Germany

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.20651-20651

2008

Volltextzugriff (PDF)

Cetuximab and cisplatin/5-FU (CF) versus CF in first-line metastatic squamous cell carcinoma of the esophagus (MESCC): A randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.4546-4546

2008

Volltextzugriff (PDF)

Continuous daily administration of sunitinib in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (mRCC): Updated results

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.5040-5040

2007

Volltextzugriff (PDF)

Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1 st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.4526-4526

2007

Volltextzugriff (PDF)

A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC)

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.4529-4529

2006

Volltextzugriff (PDF)

Intraperitoneal immunotherapy of peritoneal carcinomatosis from solid tumors by trifunctional antibodies

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.2532-2532

2004

Volltextzugriff (PDF)

Intraperitoneal immunotherapy of peritoneal carcinomatosis from solid tumors by trifunctional antibodies

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.2532-2532

2004

Volltextzugriff (PDF)

Three-weekly docetaxel (T) plus capecitabine (X) in 1 st and 2 nd line metastatic esophageal cancer (MEC): Final Results of the phase II DACAPO Trial

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.4142-4142

2005

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

KollektionWiley Online Library Full Collection 2018

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(36)

Sprache

Englisch
(36)
Japanisch
(1)

Erscheinungsjahr

n.n

Kollektion

EZB Electronic Journals Library
(36)
Ovid SocietyJournals and Single Titles
(36)
NUS Single-Journal Subscriptions
(36)
IngentaConnect Journals
(12)
Ingenta.com
(12)
MEDLINE
(5)

1 weiteren anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Positron Emission Tomography in Non–Small-Cell Lung Cancer: Prediction of Response to Chemotherapy by Quantitative Assessment of Glucose Use

Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18

Onco-PDO test utilizing patient-derived organoids (PDOs) and next-generation precision oncology in breast cancer

MOR202 with low-dose dexamethasone (Dex) and in combination with pomalidomide/dex and lenalidomide/dex in relapsed or refractory multiple myeloma (RRMM): Interim analysis of a phase I/IIa dose-escalation study

Changes in the tumor glucose-uptake measured by 18F-FDG PET with two weeks of single-agent cetuximab in localized squamous cell carcinoma of the esophagus

MOR202 alone and in combination with pomalidomide or lenalidomide in relapsed or refractory multiple myeloma: Data from clinically relevant cohorts from a phase I/IIa study

Is lanreotide and/or interferon alfa an adequate therapy for neuroendocrine tumors?

A phase I/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM)

Impact of pathologic complete response to preoperative docetaxel-based chemotherapy on disease-free survival in esophagogastric adenocarcinoma

Detection of mutant-free circulating tumor DNA in the plasma of patients with gastrointestinal stromal tumor (GIST) harboring activating mutations of C-Kit or PDGFRA

A prospective, multicenter trial of complementary and alternative medicine (CAM) utilization by patients undergoing definitive breast radiotherapy

PET-guided treatment in locally advanced adenocarcinoma of the esophagogastric junction (AEG): The MUNICON-II study

Weekly cetuximab (CET) plus oxaliplatin (OX), infusional 5-fluorouracil (5-FU) and radiation therapy (RT) as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A phase I study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Impact of chemotherapy induced haematotoxicity on blood component use and associated costs in NSCLC and lymphoma patients in Germany

Docetaxel, cisplatin and leucovorin/fluorouracil in first-line advanced gastric cancer and adenocarcinoma of the esophagogastric junction: Results of the phase II GASTRO-TAX-1 trial

Cost analysis of febrile neutropenia (FN) management in three tumour types in Germany

Cetuximab and cisplatin/5-FU (CF) versus CF in first-line metastatic squamous cell carcinoma of the esophagus (MESCC): A randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Continuous daily administration of sunitinib in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (mRCC): Updated results

Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1 st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group

A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC)

Intraperitoneal immunotherapy of peritoneal carcinomatosis from solid tumors by trifunctional antibodies

Intraperitoneal immunotherapy of peritoneal carcinomatosis from solid tumors by trifunctional antibodies

Three-weekly docetaxel (T) plus capecitabine (X) in 1 st and 2 nd line metastatic esophageal cancer (MEC): Final Results of the phase II DACAPO Trial

Aktive Filter

Suchergebnisse filtern